Gelonghui, Feb. 28 | The authoritative international journal “Vaccine” published: The world's first boron neutron capture therapy was officially approved. Currently, the only approved products in the world are the “HM-30 Neutron Irradiation System NeuCure” produced by Sumitomo Heavy Industries in Japan and the “Boron Flanged Boron Drug Steboronine” produced by Stella Pharma. According to reports, in June 2022, China Biotechnology Service Holdings (8037.HK) signed a cooperation agreement with Japan's Sumitomo Heavy Industries and Stella Pharma to determine the introduction of Japan's Sumitomo Heavy Industries neutron irradiation system “Neucure” and Stella Pharma's boron-producing drug “Steboronine” used in this study. The aim is to rely on the advantages of the Boao Lecheng Special Medical Zone system and take the lead in developing BNCT treatment services to provide internationally leading cancer treatment to domestic and Southeast Asian cancer patients as soon as possible service. Pengbo Boao Boron Neutron Hospital completed infrastructure construction in December 2023 and is currently undergoing comprehensive renovation work. In January 2024, Neucure was successfully delivered to Hainan, and equipment installation and commissioning work will soon begin. It is expected that the BNCT treatment service will be officially launched in Lecheng, Boao this year.
全球首个硼中子俘获疗法正式获批 中国生物科技服务与住友重工合作 预计今年将在博鳌乐城正式开启BNCT治疗服务
The world's first boron neutron capture therapy was officially approved. China Biotech Service and Sumitomo Heavy Industries are expected to officially launch BNCT treatment services in Lecheng, Boao this year
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.